BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 31805875)

  • 21. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn's Disease: Correlations Between Disease Activity and Long-Term Follow-Up.
    Jones GR; Fascì-Spurio F; Kennedy NA; Plevris N; Jenkinson P; Lyons M; Wong L; MacLean P; Glancy S; Lees CW
    J Crohns Colitis; 2019 Mar; 13(4):442-450. PubMed ID: 30452618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
    Shimizu H; Ebana R; Kudo T; Sato T; Hara T; Hosoi K; Usami M; Yoshida M; Takeuchi I; Nakase H; Iwama I; Arai K; Shimizu T
    J Gastroenterol; 2022 May; 57(5):344-356. PubMed ID: 35165800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between magnetic resonance enterography and ileo-colonoscopy for assessment of disease activity in terminal ileal Crohn's disease.
    Kakkar C; Singh A; Mahajan R; Midha V; Goyal S; Narang V; Gupta K; Singh D; Bansal N; Saggar K; Sood A
    Indian J Gastroenterol; 2022 Oct; 41(5):465-474. PubMed ID: 36357600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations Among Mucosal and Transmural Healing and Fecal Level of Calprotectin in Children With Crohn's Disease.
    Weinstein-Nakar I; Focht G; Church P; Walters TD; Abitbol G; Anupindi S; Berteloot L; Hulst JM; Ruemmele F; Lemberg DA; Leach ST; Cytter R; Greer ML; Griffiths AM; Turner D;
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1089-1097.e4. PubMed ID: 29501599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tight control using fecal calprotectin and early disease intervention increase the rates of transmural remission in Crohn's disease.
    Fernandes SR; Bernardo S; Saraiva S; Gonçalves AR; Moura Santos P; Valente A; Correia LA; Cortez-Pinto H; Magro F
    United European Gastroenterol J; 2024 May; 12(4):451-458. PubMed ID: 38093503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    J Clin Gastroenterol; 2018 Aug; 52(7):e53-e62. PubMed ID: 28723856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
    Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
    Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffusion-weighted imaging in quiescent Crohn's disease: correlation with inflammatory biomarkers and video capsule endoscopy.
    Klang E; Kopylov U; Eliakim R; Rozendorn N; Yablecovitch D; Lahat A; Ben-Horin S; Amitai MM
    Clin Radiol; 2017 Sep; 72(9):798.e7-798.e13. PubMed ID: 28506799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis.
    Motwani KK; Alizadeh M; Abutaleb A; Grossman J; Wellington J; Cross RK;
    Dig Dis Sci; 2024 Jun; 69(6):2154-2163. PubMed ID: 38580888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between disease duration and usefulness of fecal calprotectin measurement in patients with Crohn's disease.
    Eder P; Stawczyk-Eder K; Łykowska-Szuber L; Krela-Kaźmierczak I; Klimczak K; Szymczak A; Szachta P; Linke K
    Pol Arch Med Wewn; 2014; 124(1-2):51-7. PubMed ID: 24424551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
    Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
    Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
    Jusué V; Chaparro M; Gisbert JP
    Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
    E Penna FGC; Rosa RM; da Cunha PFS; de Souza SCS; de Abreu Ferrari ML
    BMC Gastroenterol; 2020 Feb; 20(1):35. PubMed ID: 32054445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.
    Schaffer T; Schoepfer AM; Seibold F;
    J Crohns Colitis; 2014 Sep; 8(9):1125-32. PubMed ID: 24636141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity.
    Klimczak K; Lykowska-Szuber L; Eder P; Krela-Kazmierczak I; Stawczyk-Eder K; Szymczak A; Michalak M; Studniarek A; Linke K
    Eur J Intern Med; 2015 Oct; 26(8):623-7. PubMed ID: 26198785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Relationship Between the Endoscopic Healing Index, Fecal Calprotectin, and Magnetic Resonance Enterography in Crohn's Disease.
    Smith ES; Chen J; Pan Y; Mahtani P; Lukin D; Ahmed W; Longman R; Burakoff R; Scherl E; Battat R
    J Clin Gastroenterol; 2024 Jul; 58(6):607-613. PubMed ID: 37646564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.